natgillin/translations-raw huggingface dataset:
Genvoya отговаря на критериите за не по-малка ефективност по отношение на постигане на HIV-1 РНК < 50 копия/ml, когато се сравнява с E/C/F/TDF.
Genvoya met the non-inferiority criteria in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF.
Genvoya трябва да се използва по време на бременност, само ако потенциалната полза оправдава потенциалния риск за плода.
Genvoya should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Genvoya трябва да се прекрати при пациенти с изчислен CrCl, който спада под 30 ml/min по време на лечение (вж. точки 5.1 и 5.2).
Genvoya should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see sections 5.1 and 5.2).
Genzyme A/S, (Danmark/Tanska/Danmörk), Tlf/Puh./Sími: + 45 32 71 2600
Genzyme A/S, (Danmark/Tanska/Danmörk), Tlf/Puh./Sími: + 45 32712600
Genzyme Biosurgery ApS, Oliefabriksvej 51B, DK-2770 Kastrup, Дания
Genzyme Biosurgery ApS, Oliefabriksvej 51B, DK-2770 Kastrup, Denmark
Genzyme Europe B.V
Genzyme Europe B.V.
Genzyme Europe B.V. - NL
Genzyme Europe B.V.- NL
Genzyme Europe B.V. - NL
Genzyme Europe B.V.-NL
Genzyme Europe B.V. - Нидерладния
Genzyme Europe B.V. - NL
Genzyme Europe B.V. - Холандия Да се съхранява в хладилник.
Genzyme Europe B.V. - NL Store in a refrigerator.
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, Нидерландия
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, Холандия.
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, the Netherlands
Genzyme Europe B.V., Gooimeer 10, 1411 DD, Naarden, Нидерландия
Genzyme Europe B.V., Gooimeer 10, 1411 DD, Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, 1411 DD, Naarden, Холандия
Genzyme Europe B.V., Gooimeer 10, 1411 DD, Naarden, the Netherlands
Genzyme Europe B.V., Gooimeer 10, 1411DD, Naarden, Нидерландия
Genzyme Europe B.V., Gooimeer 10, 1411DD, Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, Нидерландия
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, Нидерландия
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, The Netherlands.
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, Нидерландия.
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, The Netherlands.
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, Холандия
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, Нидерландия
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, Нидерландия
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, The Netherlands.
Genzyme Europe B.V., Gooimeer 10, NL-1411DD Naarden, Нидерландия.
Genzyme Europe B.V., Gooimeer 10, NL-1411DD Naarden, The Netherlands
Genzyme Europe BV Gooiter 10
Genzyme Europe BV Gooimeer 10
Genzyme Europe BV, Tel: +31 35 699 1200
Genzyme Europe B.V., Tel: +31 35 699 1200
Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Ирландия.
Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland.
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ирландия.
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
Genzyme Limited 37 Hollands Road Suffolk Haverhill,
Genzyme Limited 37 Hollands Road Suffolk
Genzyme Ltd.
Genzyme Ltd
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Великобритания
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Великобритания Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ирландия Bayer Schering Pharma AG, Müllerstrasse 178, D-13342 Berlin, Германия.
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom Genzyme Ireland Limited., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland Bayer Schering Pharma AG, Müllerstrasse 178, D-13342 Berlin, Germany.
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Великобритания.
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Великобритания.
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom.
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, Обединено кралство.
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom.
Genzyme Ltd.‌‌
Genzyme Ltd.
Genzyme Еurope B.V. Gooimeer 10
Genzyme Europe B.V. Gooimeer 10
George’s Respiratory Questionnaire) (SGRQ).
A pooled analysis of the
Germany
Malta
Germany
Tlf: +45 4523 5000
Ges antingen blandat med en liten fodergiva, före utfodring, eller direkt i munnen.
To be administered either mixed with a small quantity of food, prior to feeding, or directly into the mouth.
Ges antingen blandat med foder eller direkt i munnen med doseringen 0,6 mg/kg kroppsvikt, en gång dagligen i upp till 14 dagar.
To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg/kg body weight, once daily, up to 14 days.
Ges blandat i foder med dosen 0,6 mg/kg kroppsvikt, en gång dagligen i upp till 14 dagar.
To be administered mixed with food at a dose of 0.6 mg/kg body weight, once daily, up to 14 days.
Ges i munnen.
For oral use.
Ges i munnen.
Oral use.
GFR в ml/min/1,73 m2
ml/min/1.73 m2
GFRб ml/min/1,73 m2
ml/min/1.73 m2
Gilead Sciences International Limited Granta Park
Gilead Sciences International Ltd Granta Park
Gilead Sciences Intl Ltd.
Gilead Sciences International Ltd.
Gilead Sciences Ltd
Gilead Sciences Ltd.
GILENYA 0,5 mg
GILENYA 0.5 mg
Gilenya 0,5 mg твърда капсула има бяло непрозрачно тяло и ярко жълто непрозрачно капаче.
Gilenya 0.5 mg hard capsules have a white opaque body and bright yellow opaque cap.
GILENYA 0,5 mg твърди капсули
GILENYA 0.5 mg hard capsules
GILENYA 0,5 mg твърди капсули Финголимод
GILENYA 0.5 mg hard capsules Fingolimod
Gilenya в две дози (0,5 mg и 1,25 mg) е изследван в три основни проучвания при пациенти с МС.
Gilenya at two doses (0.5 mg and 1.25 mg) has been investigated in three main studies in MS patients.
Gilenya е вид лекарство, известно като „болест-модифицираща терапия“, използвано за лечение на възрастни със силно активна множествена склероза (МС).
Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults with highly active multiple sclerosis (MS).
Gilenya е лекарство, съдържащо активното вещество финголимод (fingolimod).
Gilenya is a medicine that contains the active substance fingolimod.
Gilenya е показана като самостоятелна терапия, модифицираща хода на болестта при високоактивна пристъпно-ремитентна форма на множествена склероза, при следните групи пациенти:
Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following adult patient groups:
GILENYA може да повиши риска от инфекции.
GILENYA may increase the risk of infections.
GILENYA намалява броя на лимфоцитите в периферната кръв.
GILENYA reduces peripheral blood lymphocyte counts.
Gilenya не е показана за употреба при деца и юноши на възраст под 18 години, тъй като не е проучвана при пациенти с МС под 18 години.
Gilenya is not intended to be used in children and adolescents below 18 years old as it has not been studied in MS patients below 18 years old.
Gilenya не е проучвана при пациенти с множествена склероза и захарен диабет – заболяване, свързано с повишен риск за развитие на макулен едем (вж. точка 4.4).
Gilenya has not been studied in multiple sclerosis patients with diabetes mellitus, a disease which is associated with an increased risk for macular oedema (see section 4.4).
Gilenya не е проучвана при пациенти с множествена склероза и захарен диабет.
Gilenya has not been studied in multiple sclerosis patients with concomitant diabetes mellitus.
Gilenya не е проучвана при пациенти с тежко предшестващо чернодробно увреждане (клас С по Child-Pugh) и не трябва да се прилага при такива пациенти (вж. точка 4.3).
Gilenya has not been studied in patients with severe pre-existing hepatic injury (Child-Pugh class C) and should not be used in these patients (see section 4.3).
GILENYA не се препоръчва при пациенти с:
That GILENYA is not recommended in patients with:
GILENYA не се препоръчва при пациенти със сърдечно заболяване или при такива, приемащи едновременно лекарства, за които се знае, че понижават сърдечната честота и те трябва да съобщават на всеки лекар, който посещават, че са на лечение с GILENYA.
GILENYA is not recommended in patients with cardiac disease or those taking medicines concomitantly known to decrease heart rate and they should tell any doctor they see that they are being treated with GILENYA.
GILENYA не се препоръчва при пациенти, които приемат едновременно антиаритмични лекарствени средства Клас Iа или Клас III.
GILENYA is not recommended in patients concomitantly taking Class Ia or Class III anti- arrhythmic medicines.
GILENYA не се препоръчва при пациенти, които приемат едновременно лекарства, за които се знае, че понижават сърдечната честота.
GILENYA is not recommended in patients concomitantly taking medicines which are known to decrease the heart rate.
Gilenya не трябва да се прилага при пациенти, изложени на риск от инфекции поради отслабена имунна система, пациенти с тежка инфекция или хронична активна инфекция като хепатит, рак или тежки чернодробни проблеми.
Gilenya must not be used in patients at risk of infections due to a weakened immune system, patients with a severe active infection or a long-term active infection such as hepatitis, cancer or severe liver problems.
Gilenya се използва при възрастни за лечение на пристъпно-ремитентна множествена склероза (МС), по-специално при: пациенти, които не са се повлияли въпреки предхождащото лечение с друго лекарство за лечение на МС
Gilenya is used in adults to treat relapsing-remitting multiple sclerosis (MS), more specifically in: Patients who have failed to respond despite treatment with an MS treatment. or
Gilenya се използва при „пристъпно-ремитентна“ МС, при която пациентите имат пристъпи (рецидиви), последвани от периоди без симптоми (ремисии).
Gilenya is used in the type of MS known as ‘relapsing- remitting’, when the patient has attacks (relapses) in between periods with decreased symptoms (remissions).
Gilenya се предлага в опаковки, съдържащи 7, 28 или 98 капсули или в групови опаковки, съдържащи 84 капсули (3 опаковки по 28 капсули).
Gilenya is available in packs containing 7, 28 or 98 capsules or in multipacks containing 84 capsules (3 packs of 28 capsules).
Gilenya трябва да се използва с повишено внимание при такива пациенти поради потенциалното повишаване на риска от развитие на макулен едем (вж. точки 4.4 и 4.8).
Gilenya should be used with caution in these patients due to a potential increase in the risk of macular oedema (see sections 4.4 and 4.8).
Gimeracil poveča izpostavljenost za 5-fluorouracil (5-FU), tako da zavira DPD, primarni encim, odgovoren za presnovo 5-FU.
Gimeracil increases 5-fluorouracil (5-FU) exposure by inhibiting DPD, the primary enzyme for metabolizing 5-FU.
Gimeracil se primarno izloča prek ledvic (glejte poglavje 5.2); tako se pri bolnikih z insuficienco ledvic zmanjša ledvični očistek gimeracila, izpostavljenost za 5-FU pa se poveča.
Gimeracil is primarily cleared by the kidney (see section 5.2); so, in patients with renal insufficiency gimeracil renal clearance is decreased and 5-FU exposure thus increased.
Gimeracil zavira presnovo snovi 5-FU, tako da reverzibilno in selektivno zavira DPD, primarni encim, odgovoren za presnovo 5-FU, s čimer je mogoče doseči večjo koncentracijo snovi 5-FU v plazmi ob uporabi manjšega odmerka tegafurja.
Gimeracil inhibits the metabolism of 5-FU by reversibly and selectively inhibiting DPD, the primary metabolic enzyme for 5-FU, so that higher plasma concentrations of 5-FU are achieved with the administration of a lower dose of tegafur.
GINA 4 (%)
GINA 4,
GINA 5 (%)
GINA 5,
GIOTRIF 20 mg таблетки афатиниб
GIOTRIF 20 mg tablets afatinib
GIOTRIF 20 mg филмирани таблетки афатиниб
GIOTRIF 20 mg film-coated tablets afatinib
GIOTRIF 20 mg филмирани таблетки са бели до жълтеникави и кръгли.
GIOTRIF 20 mg film-coated tablets are white to yellowish and round shaped.
GIOTRIF 30 mg таблетки афатиниб
GIOTRIF 30 mg tablets afatinib
GIOTRIF 30 mg филмирани таблетки афатиниб
GIOTRIF 30 mg film-coated tablets afatinib
GIOTRIF 30 mg филмирани таблетки са тъмносини и кръгли.
GIOTRIF 30 mg film-coated tablets are dark blue and round shaped.
GIOTRIF 40 mg таблетки афатиниб
GIOTRIF 40 mg tablets afatinib
GIOTRIF 40 mg филмирани таблетки афатиниб
GIOTRIF 40 mg film-coated tablets afatinib
GIOTRIF 40 mg филмирани таблетки са светлосини и кръгли.
GIOTRIF 40 mg film-coated tablets are light blue and round shaped.
GIOTRIF 50 mg таблетки афатиниб
GIOTRIF 50 mg tablets afatinib
GIOTRIF 50 mg филмирани таблетки афатиниб
GIOTRIF 50 mg film-coated tablets afatinib
GIOTRIF 50 mg филмирани таблетки са тъмносини и овални.
GIOTRIF 50 mg film-coated tablets are dark blue and oval shaped.
GIOTRIF може да Ви бъде предписано като първо лечение или ако предходната Ви химиотерапия не е била достатъчна. от плоскоклетъчен тип, ако предходната Ви химиотерапия не е била достатъчна.
GIOTRIF can be prescribed to you as your first treatment or if prior chemotherapy treatment has been insufficient. of squamous type if prior chemotherapy treatment has been insufficient.
GIOTRIF не е проучван при пациенти с eGFR <15 ml/min/1,73 m² или такива на диализа.
GIOTRIF has not been studied in patients with eGFR <15 mL/min/1.73m² or on dialysis.
Girona SPAIN
SPAIN
Girona ИСПАНИЯ
Girona SPAIN
Girona ИСПАНИЯ
SPAIN
Glasier et al, Lancet 2010
2: Glasier et al, Lancet 2010
Glavna merila za nevključitev bolnikov so bila potrjena peptična ulkusna bolezen v preteklih 6 mesecih, predhodna intracerebralna krvavitev, pomembna trombocitopenija (število trombocitov
The major exclusion criteria for patients were documented peptic ulcer disease within the previous
Glavna presnovna pot za tegafur poteka prek pretvorbe v 5-FU z encimom CYP2A6 v jetrih, medtem ko je gimeracil stabilen v homogenatu človeških jeter (frakcija S9) z adenozin 3’-fosfat 5'-fosfosulfat litijevo soljo (PAPS; kofaktor za sulfotransferazo) ali nikotinamid adenin dinukleotid fosfatom (NADPH).
The main metabolic pathway for tegafur is through conversion to 5-FU via CYP2A6 in the liver, whereas gimeracil was stable in human liver homogenate (S9 fraction) with adenosine 3’-phosphate 5'-phosphosulfphate lithium salt (PAPS; a co-factor for sulfotransferase) or nicotinamide adenine dinucleotide phosphate (NADPH).
Glavni produkt razgradnje pravastatina je izomerni metabolit 3-α-hidroksi.
The major degradation product of pravastatin is the 3-α- hydroxy isomeric metabolite.
Glavobol
Headache
glavobol vrtoglavica
Headache Dizziness
glavobol,
Headache
Glaxo Group Limited
Glaxo Group Limited 980 Great West Road, Brentford,
Glaxo Group Limited 980 Great West Road Brentford
980 Great West Road Brentford
Glaxo Group Limited 980 Great West Road Brentford, Middlesex,
Glaxo Group Limited 980 Great West Road, Brentford,
Glaxo Group Limited 980 Great West Road, Brentfortd, Middlesex,
Glaxo Group Limited 980 Great West Road, Brentford,
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS, Великобритания.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Великобритания Glaxo Group Ltd лого
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS United Kingdom Glaxo Group Ltd logo
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Великобритания Glaxo Group Ltd лого
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom Glaxo Group Ltd logo
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Великобритания.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Великобритания.
Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
Glaxo Group Ltd лого
Glaxo Group Ltd logo
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, Великобритания
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Великобритания
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Великобритания Производител:
Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom Manufacturer:
Glaxo Group Ltd, Greenford, Middlesex, UB6 0NN, Великобритания
Glaxo Group Ltd, Greenford, Middlesex, UB6 0NN, United Kingdom
Glaxo Operations UK Limited (trading as Glaxo Wellcome
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations)
Glaxo Operations UK Limited (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12 8DT, Великобритания.
Glaxo Operations UK Limited (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12 8DT, United Kingdom.
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations): Harmire Road, Barnard Castle, County Durham DL12 8DT, Великобритания.
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations): Harmire Road, Barnard Castle, County Durham DL12 8DT, United Kingdom.
Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, Великобритания
Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, United Kingdom
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK, Ltd,(trading as Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG 12 0DJ, Великобритания.
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG 12 0DJ, United Kingdom.
Glaxo Operations UK Ltd. (trading as Glaxo Wellcome Operations) Priory Street
Glaxo Operations UK Ltd. (trading as Glaxo Wellcome Operations) Priory Street‌
Glaxo Wellcome GmbH & Co.KG
Glaxo Wellcome GmbH & Co. KG
Glaxo Wellcome Operations, Priory Street, Ware, Hertfordshire SG12 0DJ, Великобритания
Glaxo Wellcome Operations, Priory Street, Ware, Hertfordshire SG12 0DJ, United Kingdom
Glaxo Wellcome S.A. Avenida de Extremadura 3
Glaxo Wellcome S.A. Avenida de Extremadura 3 09400 Aranda de Duero Burgos
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero Burgos, Испания
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero Burgos, Spain.
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero Burgos, Испания.
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero, Burgos, Spain.
GlaxoSmithKline (GSK) S.R.L. Tel: + 4021 3028 208
GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000
GlaxoSmithKline (GSK) S.R.L. Tel: + 4021 3028 208
Tel: + 4021 3028 208
GlaxoSmithKline (GSK) S.R.L. Tel: + 4021 3028 208 www.gsk.ro
GlaxoSmithKline (GSK) S.R.L. Tel: + 4021 3028 208
GlaxoSmithKline (GSK) SRL Tel: + 40 (0)21 3028 208
GlaxoSmithKline (GSK) SRL Tel: +40 (0)21 3028 208
GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000
GlaxoSmithKline (GSK) S.R.L. Tel: + 4021 3028 208
GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000
GlaxoSmithKline (Ireland) Limited
GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 495 5000
GlaxoSmithKline (Ireland) Ltd
GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 4955000
GlaxoSmithKline (Ireland) Ltd
GlaxoSmithKline (Malta) Limited Tel: + 356 21 238131
GlaxoSmithKline (Malta) Limite Tel: + 356 21 238131
GlaxoSmithKline (Malta) Limited Tel: + 356 21 238131
GlaxoSmithKline (Malta) Limited Tel: + 356 21 238131 dk-info@gsk.com
GlaxoSmithKline (Malta) Limited Tel: + 356 21 238131
Nederland GlaxoSmithKline BV Tel: + 31 (0)30 6938100 nlinfo@gsk.com
GlaxoSmithKline - Eesti OÜ Tel: +372 667 6900 estonia@gsk.com
GlaxoSmithKline Eesti OÜ Tel: +372 667 6900 estonia@gsk.com
GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com
Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com
GlaxoSmithKline Biologicals
GlaxoSmithKline Biologicals‌
GlaxoSmithKline Biologicals S.A. 2100 Gödöllö, Táncsics Mihály út 82 Унгария
GlaxoSmithKline Biologicals S.A. 2100 Gödöllö, Táncsics Mihály út 82 Hungary
GlaxoSmithKline Biologicals S.A. 89 rue de I’Institut-1330 Rixensart Белгия
GlaxoSmithKline Biologicals S.A. 89 rue de I’Institut-1330 Rixensart Belgium
GlaxoSmithKline Biologicals S.A. 89, rue de l’Institut
GlaxoSmithKline Biologicals S.A. 89, rue de l'Institut
GlaxoSmithKline Biologicals S.A. 89, rue de l’Institut – 1330 Rixensart Белгия
GlaxoSmithKline Biologicals S.A. 89, rue de l’Institut – 1330 Rixensart Belgium
GlaxoSmithKline Biologicals SA Parc de la Noire Epine rue Flemming 20-1300 Wavre Белгия
GlaxoSmithKline Biologicals SA Parc de la Noire Epine rue Flemming 20-1300 Wavre Belgium
GlaxoSmithKline Consumer Healthcare A/S Tlf: + 45 44 86 86 00
GlaxoSmithKline Consumer Healthcare A/S Tlf: + 45 80 25 16 27
GlaxoSmithKline Consumer Healthcare BV Tel: + 31 (0)30 6938780
GlaxoSmithKline Consumer Healthcare BV Tel: + 31 (0)30 693 8780
GlaxoSmithKline Consumer Healthcare Tlf: + 47 22 70 2201
GlaxoSmithKline Consumer Healthcare Tlf: + 47 80 05 86 30
GlaxoSmithKline Consumer Healthcare UK Tel: + 44 (0)800 171 2014 (Freephone)
GlaxoSmithKline Consumer Healthcare Tel: + 44 (0)800 171 2014 (Freephone) customer.relations@gsk.com
GlaxoSmithKline Consumer Healthcare UK Tel: + 44 (0)800 171 2014 (Freephone)
GlaxoSmithKline Consumer Healthcare Tel: + 44 (0)800 171 2014(Freephone) customer.relations@gsk.com
GlaxoSmithKline Consumer Healthcare – Produtos para a Saúde e Higiene, Lda, Lda.
GlaxoSmithKline Consumer Healthcare – Produtos para a Saúde e Higiene, Lda.
GlaxoSmithKline Cyprus Ltd
GlaxoSmithKline (Cyprus) Ltd
GlaxoSmithKline Cyprus Ltd Τηλ: + 357 22 39 70 00
GlaxoSmithKline (Cyprus) Ltd Τηλ: + 357 22 39 70 00
GlaxoSmithKline d.o.o.
Slovenija GlaxoSmithKline d.o.o.
GlaxoSmithKline d.o.o.
Tel.: + 385 (0)1 6051999
GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk.com
GlaxoSmithKline Eesti OÜ
GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk.com
GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900
GlaxoSmithKline Eesti OÜ Tel: + 372 6676 979
GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900
GlaxoSmithKline GmbH & Co.
GlaxoSmithKline GmbH & Co. KG
GlaxoSmithKline Kft.
Magyarország GlaxoSmithKline Kft.
GlaxoSmithKline Latvia SIA
GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk.com
GlaxoSmithKline Latvia SIA Tel: + 371 6 7312687 lv-epasts@gsk.com
GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk.com
GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk.com
GlaxoSmithKline Latvia SIA
GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk.com
GlaxoSmithKline Latvia SIA Tel: + 371 67312687
GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk.com
GlaxoSmithKline Latvia SIA Tel: + 371 7312687 lv-epasts@gsk.com
GlaxoSmithKline Latvia SIA Tel: + 371 67312687 lv-epasts@gsk.com
Tel: + 371 67312687 lv-epasts@gsk.com
GlaxoSmithKline Latvia SIA Tel: + 371 7312687 lv-epasts@gsk.com
GlaxoSmithKline Latvia SIA
GlaxoSmithKline Lietuva UAB Tel. +370 5 264 90 00 info.lt@gsk.com
GlaxoSmithKline Lietuva UAB Tel. +370 264 90 00 info.lt@gsk.com
GlaxoSmithKline Lietuva UAB Tel. +370 5 264 90 00 info.lt@gsk.com
GlaxoSmithKline Lietuva UAB Tel: +370 5 264 90 00 info.lt@gsk.com
GlaxoSmithKline Lietuva UAB Tel: + 370 5 264 90 00
GlaxoSmithKline Lietuva UAB Tel: + 370 5 264 90 00 info.lt@gsk.com
GlaxoSmithKline Lietuva UAB Tel: + 370 5 264 90 00 info.lt@gsk.com
GlaxoSmithKline Lietuva UAB Tel: + 370 5 264 90 00